SRPT - Sarepta Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

SRPT is currently covered by 26 analysts with an average price target of $50.15. This is a potential upside of $31.77 (172.85%) from yesterday's end of day stock price of $18.38.

Sarepta Therapeutics's activity chart (see below) currently has 680 price targets and 638 ratings on display. The stock rating distribution of SRPT is 78.42% BUY, 15.11% HOLD and 6.47% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 56.82% with an average time for these price targets to be met of 271.67 days.

Highest price target for SRPT is $150, Lowest price target is $10, average price target is $92.

Most recent stock forecast was given by ANUPAM RAMA from JPMORGAN on 10-Jul-2025. First documented stock forecast 20-Mar-2013.

Currently out of the existing stock ratings of SRPT, 109 are a BUY (78.42%), 21 are a HOLD (15.11%), 9 are a SELL (6.47%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$28

$9.83 (54.10%)

$84

6 days ago
(10-Jul-2025)

9/18 (50%)

$8.93 (46.83%)

125

Hold

$10

$-8.17 (-44.96%)

$10

21 days ago
(25-Jun-2025)

8/14 (57.14%)

$-7.46 (-42.73%)

55

Buy

$40

$21.83 (120.14%)

$200

28 days ago
(18-Jun-2025)

5/8 (62.5%)

$19.23 (92.59%)

271

Buy

$30

$11.83 (65.11%)

$193

29 days ago
(17-Jun-2025)

41/58 (70.69%)

$8.44 (39.15%)

290

Buy

$40

$21.83 (120.14%)

$113

29 days ago
(17-Jun-2025)

17/29 (58.62%)

$18.44 (85.53%)

294

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is SRPT (Sarepta Therapeutics) average time for price targets to be met?

On average it took 271.67 days on average for the stock forecasts to be realized with a an average price target met ratio 56.82

Which analyst has the current highest performing score on SRPT (Sarepta Therapeutics) with a proven track record?

DIFEI YANG

Which analyst has the most public recommendations on SRPT (Sarepta Therapeutics)?

Difei Yang has 22 price targets and 20 ratings on SRPT

Which analyst is the currently most bullish on SRPT (Sarepta Therapeutics)?

Mani Foroohar with highest potential upside - $211.83

Which analyst is the currently most reserved on SRPT (Sarepta Therapeutics)?

Steve Brozak with lowest potential downside - -$79.57

Sarepta Therapeutics in the News

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you...

Robbins LLP Reminds Sarepta Therapeutics, Inc. Investors with Large Losses to Contact the Firm for Information About the SRPT Class Action Lawsuit

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?